一圖看懂潤邁德-B(2297.HK)IPO
潤邁德-B(2297.HK)於6月27日-6月30日招股,公司擬全球發售2334.80萬股,其中香港發售233.60萬股,國際發售2101.20萬股。招股價爲4.28港元-6.24港元,每手1000股,入場費爲6302.89港元,預計將於7月8日在港交所上市。聯席保薦人爲華泰國際,並且此前曾獲平安資本、景林資產、同創偉業、輕舟資本、Seresia Asset Management、Lighthouse Canton等衆多海內外知名機構支持。
潤邁德醫療創始於2014年,致力於成爲全球領先的血管介入手術機器人公司。目前,公司專注於機器人系統數字化功能診斷模塊兩款核心產品——冠狀動脈血流儲備分數(caFFR)系統、冠狀動脈造影微血管阻力指數(caIMR)系統,FlashBot血管介入手術機器人及其他兩款在研產品的研發、生產及商業化。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.